Deferiprone at a dose of 75 mg/kg/day is not sufficiently effective to maintain iron stores at a level which has been considered safe in all patients with iron overload. Our main aim was to determine the safety of long-term therapy with high-dose (100 mg/kg/day) deferiprone. A secondary aim was to determine the efficacy of this high dose. Twelve thalassemia major patients received deferiprone at a dose of100 mg/kg/day over 2 years. Transient aspartate aminotransferase increase (8 patients), gastrointestinal discomfort (3 patients) and arthralgia (2 patients) were the most commonly reported side effects. None of the patients discontinued therapy. The mean serum ferritin level fell from 3,901 ± 3,618 to 1,790 ± 2,205 µg/l after 2 years (p < 0.05). Five of the 12 patients continued to receive deferiprone for an additional 3 years. No new side effects were encountered. The mean serum ferritin level in this subgroup was initially 2,510 ± 332 µg/l and dropped to 1,511 ± 664 µg/l after 5 years (p < 0.05). Liver iron levels at the end of the 2-year study ranged from 1.0 to 30.9 mg/g dry weight, 3 of the patients having levels above 15 mg/g.

Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S: Survival and causes of death in thalassaemia major. Lancet 1989;ii:27–30.
Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567–573.
Hoffbrand AV, AL-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B: Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295–300.
Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA: Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417–423.
Taher A, Chamoun FM, Koussa S, Saad MA, Khoriaty AI, Neeman R, Mourad FH: Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. Acta Haematol 1999;101:173–177.
Barry M, Sherlock S: Measurement of liver iron content in liver biopsy specimen. Lancet 1971;1:100–103.
Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN: Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–699.
Scheuer PJ, Lefkowitch JH: Liver Biopsy Interpretation, ed 6. London, Saunders, 2000, p 274.
Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B: Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995;91:224–229.
Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F: Safety profile of the oral iron chelator deferiprone: A multicentre study. Br J Haematol 2000;108:305–312.
Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefano I, Tricta F: The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330–336.
Hoffbrand AV, Cohen A, Hershko C: Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17–24.
Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT: Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992;82:460–466.
Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G: Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995;332:918–922.
Maggio A, D’Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, D’Ascola DG, Rizzo A, Midiri M: Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial. Blood Cells Mol Dis 2002;28:196–208.
Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F: Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583–1587.
Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, Frau MR, Faa G, Diana G, Dessi C: Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994;125:123–128.
Ardalan FA, Osquei MR, Toosi MN, Irvanloo G: Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: A retrospective cross-sectional study. BMC Gastroenterol 2004;4:17.
Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR: Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002;36:687–691.
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516–520.
Piga A, Gaglioti C, Fogliacco E, Tricta F: Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis. Haematologica 2003;88:489–496.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.